在小儿神经性膀中,Mirabegron-抗胆固醇组合的长期疗效
Arash K Taghizadeh1, Jo Clothier2, Anna Page2
1Department of Paediatric Urology, Evelina London Children's Hospital, Westminster Bridge Road, London, SE1 7EH, UK; Department of Women and Children's Health, School of Life Course Sciences, Kings College London, London, UK.
Journal of pediatric urology
|January 4, 2025
概括
米拉贝格朗-抗胆固醇组合有效地控制了儿科的神经性膀,在大多数儿童中,膀功能和症状持续改善超过三年. 这种组合疗法为耐火病例提供了一个有希望的长期解决方案.
科学领域:
- 儿科泌尿外科 儿科泌尿外科
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 儿童的神经性膀往往需要先进的治疗策略.
- 米拉贝格朗-抗胆固醇 (MAC) 组合是一种公认的升级疗法,用于治疗儿科的神经性膀.
- 以前的治疗方法,如抗胆固醇药物和肉毒毒素 (BTX),可能并不总是足够的.
研究的目的:
- 评估Mirabegron-抗胆固醇 (MAC) 组合在患有神经性膀的儿童中的长期疗效.
- 评估VUD的持久性和症状改善.
- 确定影响治疗成功和潜在不良事件的因素.
主要方法:
- 从2015年至2023年期间,对接受Mirabegron和抗胆固醇药物治疗的儿科患者进行了回顾性图表审查.
- 纳入标准:至少2年的VUD随访和3.5年的症状随访,所有使用干净间歇性导管 (CIC) 的患者.
- 通过VUD数据,症状报告和不良事件评估有效性;统计分析包括中位数值和非参数测试.
主要成果:
- 在MAC治疗后观察到膀容量,服从性和最大解毒器压力的显著改善,在31名患者中21名患者中维持在33个月的中位数.
- 在19名患者中,症状改善持续了平均43个月.
- 副作用是最小的,血压或上道状况没有显著变化.
结论:
- 该MAC组合有效治疗抗胆固醇和BTX疗法耐药的儿科神经性膀.
- 在显著的合规性损失之前启动VUD和症状的好处是长期维持的 (平均33个月和43个月).
- 在儿童神经性膀管理中,MAC是一种有希望的,持久的治疗选择.
相关概念视频
The Micturition Reflex
419
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
419
Cholinergic Antagonists: Therapeutic Uses
709
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
709
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
613
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
613
Cholinergic Antagonists: Pharmacokinetics
408
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
408
Cholinergic Antagonists: Pharmacological Actions
859
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
859
Direct-Acting Cholinergic Agonists: Therapeutic Uses
683
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
683


